Avelumab First-Line Maintenance (1LM) in Advanced Urothelial Carcinoma (aUC): Conditional Survival and Long-Term Safety in Patients (pts) Treated for ≥1 or ≥2 Years in the JAVELIN Bladder 100 Phase 3 Trial